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What Is PARV4?
PARV4 was first reported in 2005 in a hepatitis B virus–infected
injecting drug user (IDU) [1]. It was detected by a screening
process that aimed to identify new DNA viruses in subjects
reporting risk factors for HIV combined with nonspecific
symptoms of ‘‘viral infection syndrome’’, including fatigue,
malaise, and headache [1].
PARV4 belongs to the Parvovirus family, characterised by
small, non-enveloped, single-stranded DNA viruses, with an
icosahedral capsid. Parvoviruses infect a diverse range of hosts,
and are divided into subfamilies Parvovirinae and Densovirinae,
infecting vertebrates and arthropods respectively. PARV4 is one of
only four groups of parvovirus known to infect humans, the others
being parvovirus B19, human bocavirus, and adeno-associated
viruses (Figure 1A, 1B).
The genome of PARV4 is approximately 5 kB long and
comprises two open reading frames (ORFs), encoding three genes
(Figure 1C). ORF-1 encodes a nonstructural protein (NS-1)
essential for viral replication and also potentially responsible for
cytopathic effects, as it can induce cell cycle arrest in vitro [2].
ORF-2 divides into two overlapping structural proteins, viral
capsid proteins 1 and 2 (VP-1 and VP-2; Figure 1C). There is no
in vitro culture system for PARV4, and it is unknown whether the
virus can replicate autonomously.
What Is the Origin of PARV4 in Humans?
PARV4 isolates have been subclassified into three genotypes
(Figure 1B). Genotypes 1 and 2 (the latter originally termed PARV5)
are predominant in Europe, North America, and Asia [3,4];
genotype 3 is most widespread in Africa [5,6]. Genetic diversity
within each genotype is minimal, leading to one possible inference
that the spread of each has been a relatively recent phenomenon,
likely originating within the past 20–30 years [4]. It is possible that
the three genotypes represent separate zoonotic transmissions of
PARV4 into human populations, perhaps from chimpanzees and
monkey species that harbour the most closely related parvoviruses
to PARV4 [4,7]. However, in a recent study [8], the nonhuman
PARV4-like variants were species-specific, despite frequent oppor-
tunities for transmission, including blood contact, between nonhu-
man primates and human hunters. Despite its scarcity in Western
countries, PARV4 may, alternatively, represent the human lineage
of a parvovirus that has remained species-specific throughout the
evolution of the Partetravirus genus.
Who Gets PARV4 and How Is It Transmitted?
(1) Evidence for parenteral and vertical transmission
To date, the best evidence about PARV4 transmission comes
from IDU cohorts in Europe and North America, in which PARV4
is strongly associated with hepatitis C virus (HCV) and HIV
infection: up to 95% of individuals with these viruses are positive for
PARV4 IgG [9]. Likewise, in China, PARV4 infection has been
strongly associated with the presence of either chronic hepatitis B
virus (HBV) or HCV [3], and in a United Kingdom autopsy series,
PARV4 DNA was found only in subjects coinfected with HIV [4].
However, parenteral transmission is also clearly possible
independently from other blood-borne viruses, and PARV4 IgG
has been reported in the absence of HIV, HBV, or HCV in the
IDU population [10], in haemophilia patients [11], and in patients
with a history of intra-muscular injections [12]. The potential for
placental transmission has also been documented in a small series
from Taiwan, in which neonates with PARV4 viraemia were born
to IgM positive mothers [13].
PARV4 infections in European or North American populations
are rare in individuals without risk factors for blood-borne viruses,
suggesting little or no transmission in the general population.
Indeed, even within households of PARV4-positive haemophiliacs,
contacts are IgG negative [11].
(2) Evidence for non-parenteral transmission
Alternative transmission routes are suggested by cohorts in
which the background population has a higher prevalence of
PARV4 IgG antibodies, and by PARV4-positive individuals who
lack risk factors for parenteral transmission. One North American
study, surprisingly, found PARV4 in 2% of plasma samples [14],
although this prevalence should be interpreted with caution,
because the risk factors for blood borne viruses in donors are not
well characterised. In this study, fluctuations in the rate of PARV4
were postulated to reflect seasonal variation or bouts of epidemic
transmission [14].
Even higher rates of PARV4 IgG seropositivity are reported in
different geographic locations, strongly suggesting non-parenteral
transmission. Up to 22% of HBV/HCV-negative individuals in a
Chinese cohort were IgG positive [3], and around one in three
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Figure 1. Genetics and genomics of PARV4. (A) Neighbour-joining phylogenetic tree reconstructed using amino acid sequences of ORF-1
(nonstructural protein) of Parvovirinae species. Sequences downloaded from NCBI (https://www.ncbi.nlm.nih.gov/genbank/). Sequences were
selected based on completeness of sequence (minimum 621 amino acids per sequence), date of publication (all published between 2002 and 2010),
and to provide representative viruses within each of the major Parvovirinae genera. Alignments and tree reconstruction were performed using
Clustalw2 (http://www.ebi.ac.uk/Tools/msa/clustalw2). Subfamilies Densovirinae and Parvovirinae are indicated by dashed ovals. Genera within
Parvovirinae are indicated by solid-coloured ovals and labelled with newly proposed genus nomenclature [23]. Viruses known to cause human
infection are marked ‘*’. PARV4 genotypes 1–3 are in a new genus variously termed Partetravirus or Tetraparvovirus, together with animal
parvoviruses (bovine and porcine hokovirus and PARV4-like viruses infecting nonhuman primates [8]) to which they are most closely related [2,23].
Individual taxa are as follows, with GenBank ID in square brackets: PARV_1= PARV4 genotype 1 [ACD71480.1]; PARV_2= PARV4 genotype 2
[ABV71690.1]; PARV_3= PARV4 genotype 3 [ACF94533.1]; PARV4_ch=PARV4-like virus of chimpanzees [AFD01617]; PARV4_co= PARV4-like virus of
colobus monkey [AFD01599]; PHoV=porcine hokovirus [ADN44557.1]; BHoV=bovine hokovirus [ABY67685.1]; AAV_1= adeno-associated virus 1
[AAU05367.1]; AAV_7= adeno-associated virus 7 [YP_077177.1]; AAV_8= adeno-associated virus 8 [YP_077179.1]; B19= human parvovirus B19
[ABC87246.1]; AMDV=Aleutian mink disease virus [ACY54678.1]; MVM=minute virus of mice [ABB01353.1]; AADV=Aedes aegypti densovirus
[YP_002854229.1]. Percentage amino acid sequence identity for tetraparvoviruses in comparison to PARV_1, calculated for NS1 protein using
ClustalW2, are as follows: PARV4 _2, 96.4%; PARV4_3, 97.0%; PARV4_ch, 91.5%; PARV4_co, 67.8%; BHoV, 59.5%; PHoV, 58.1%. (B) Neighbour-joining
phylogenetic tree reconstructed using full-length nucleotide sequences of species within the Tetraparvovirus subfamily. Methods and individual
isolates as for Figure 1A. Percentage nucleotide sequence identity in comparison to PARV_1, calculated for full-length sequence using ClustalW2, are
as follows: PARV4 _2, 92.1%; PARV4_3, 92.9%; PARV4_ch, 83.3%; PARV4_co, 71.3%; BHoV, 65.1%; PHoV, 65.3%. (C) Schematic diagram of PARV4
genome. Diagram based on NCBI Reference Sequence: NC_007018.1 [1]. Open Reading Frame 1 (ORF-1) encodes Non-Structural Protein 1 (NS-1); this
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adults in a variety of sub-Saharan African locations is positive in
the absence of other blood-borne viruses [15]. Although a
proportion of these cases may be parenterally transmitted
(probably relating to iatrogenic exposures) [12], others may be
acquired by alternative routes—although identifying these is
problematic. A study of West African children with respiratory
or gastrointestinal symptoms revealed the presence of PARV4
DNA in 0.5–0.8% of nasal and faecal specimens, suggesting the
potential for either respiratory and/or faeco-oral transmission
[16]. In another study of Ghanaian children, demographic factors
were identified as markers of infection risk, including lack of access
to a kitchen and living close to a river [6].
Does PARV4 Cause Clinical Symptoms?
There is currently no definitive clinical syndrome associated
with PARV4 infection, and the potential pathogenicity of related
hokoviruses in animals is also unknown [17]. In the majority of
instances, PARV4 viraemia appears to be self-limiting and
asymptomatic [6], and there is no consistent association with
increased severity of co-existing blood-borne viruses [3].
However, in a minority of reports, a range of possible disease
outcomes are described in individuals with evidence of past or
current PARV4 infection, including respiratory or gastrointestinal
symptoms, hepatitis, rash, and encephalitis (Table 1). Notably,
most of these studies describe small numbers of patients, and none
is definitively able to attribute clinical manifestations to the
presence of PARV4. Establishing cause and effect is further
confounded by the close relationship between PARV4 and other
blood-borne viruses; for example, although a statistical correlation
has been described between PARV4 positivity and early features
of AIDS, this association is potentially confounded by the close
relationship between PARV4 and both HCV status and individ-
uals with a history of IDU [9].
How Is PARV4 Infection Diagnosed and
Documented?
Evidence of PARV4 infection is most frequently detected by an
ELISA for specific IgG antibody to VP-2 [11]. This response
appears to be sustained over time, as with other parvovirus
infections; weak or transient VP-2 IgM positivity has also been
reported in acute infection [11].
PARV4 DNA may be isolated from plasma in acute infection,
generally with low viral loads (e.g. #36104 copies/ml) [11,18],
although acute viraemia of up to 1010 copies/ml has been reported
[11]. Asymptomatic viraemia was reported in 8% of children in a
Ghanaian cohort [6]. Different studies have reported the duration
of viraemia lasting from 30 days [10] up to a mean of 7 months
[11]. However, recrudescence or reinfection could also explain
these relatively prolonged durations of viraemia [18]. Despite
these reports of isolation of PARV4 DNA from serum [10,11,18],
region is responsible for potentially cytopathic effects of the virus [2]. Open Reading Frame 2 (ORF-2) comprises overlapping proteins Viral Protein 1
(VP-1) and Viral Protein 2 (VP-2), which encode structural capsid proteins. Protein lengths are shown as number of amino acids (aa). Additional
Reading Frames (ARFs) are conserved across PARV4 genotypes; shown as ARF-1 (67 amino acids) and ARF-2 (86 amino acids) [5].
doi:10.1371/journal.ppat.1004036.g001
Table 1. Clinical symptoms reported in subjects with PARV4 infection.
Reference
Characteristics and location of
subject(s) with PARV4 infectiona
Method of laboratory detection
of PARV4 infection Presenting clinical symptoms(s)
Benjamin et al., 2011 [21] N= 2; children aged 2–3 years with
suspected CNS infection; India.b
PARV4 DNA in CSF Presumed encephalitis (fever and generalised
convulsions).
Chen et al., 2011 [13] N= 6; mother-infant pairs with
nonimmune idiopathic hydrops
in foetus; Taiwan.
Infants: five of six had PARV4 DNA in
plasma.Mothers: four of six had PARV4
IgM; two of six had PARV4 IgG
Foetal hydrops ($2 of ascites, pleural/
pericardial effusion, skin oedema,
polyhydramnios). Two of six babies died.
Drexler et al., 2012 [16] N= 13; Children with respiratory or
gastrointestinal symptoms; Ghana.c
PARV4 DNA in nasal secretions (N = 8,
median age 32 months) or faeces
(N = 5, median age 43 months).
Upper/lower respiratory tract symptoms or
gastrointestinal symptoms.
Jones et al., 2005 [1] N= 1; homeless male IDU, Hepatitis
B-positive, HIV-negative; United
States.
PARV4 DNA in serum. Fatigue, arthralgia, neck stiffness, pharyngitis,
diarrhoea, vomiting, confusion, night sweats.
Sharp et al., 2012 [11] N= 9; haemophilia patients aged
10–21 years seroconverting to
PARV4 IgG positivity over a 5-year
period (seven were already
HIV-positive); HGDS cohort, US.
Conversion from PARV4 IgG negative
to positive; two had transient positive
PARV4 IgM. All were positive for PARV4
DNA in serum (viral titre ,103–1010
copies/ml)
Rash in three subjects, unexplained hepatitis
(but minimal disturbance of LFTs at the time of
PARV4 IgG seroconversion).
Simmons et al., 2012 [9] N= 193; subjects from Swiss HIV
Cohort Study (www.shcs.ch/).
PARV4 IgG positive. Early HIV-related symptoms (CDC-B
symptoms).
Vallerini et al., 2008 [22] N= 1; patient with Wegener’s
Granulomatosis on long-term
steroid therapy; Italy.b
PARV4 DNA in serum. Fever, anaemia (with erythroid hypoplasia on
bone marrow biopsy), post-infectious
glomerulonephritis, subsequent multiorgan
failure.
Papers are listed in alphabetical order by first author.
aDenominator presented is the number of individuals positive for PARV4 (extrapolated from total number of subjects studied in each paper), except for Simmons et al.
[9], where denominator is number with HIV.
bOther infectious causes of the clinical syndrome were excluded.
cOther pathogens were also present which may have explained the clinical syndrome.
CNS= central nervous system; CSF= cerebrospinal fluid; IDU = injecting drug user; LFTs = liver function tests.
doi:10.1371/journal.ppat.1004036.t001
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this is generally uncommon, suggesting that immune containment
is good even in immunocompromised hosts [4].
Is PARV4 Cleared after Acute Infection?
Like other human parvoviruses, PARV4 has the potential for
persistence: DNA can be extracted from tissue long (indeed,
possibly life-long) after primary infection [4,19]. This is also
supported by a high frequency and magnitude of T-cell responses
to PARV4 (detected in vitro by Interferon-gamma ELISpot assays)
[20], similar to that which is seen in response to other chronic or
latent viral infections—the best characterised examples being the
herpesviruses CMV and EBV.
It is not known exactly which tissues are reservoirs for PARV4,
either in the acute or chronic phases of infection. However,
different studies have described the detection of PARV4 DNA
from a variety of sites including blood, lymphoid tissue, bone
marrow, liver, and central nervous system [1,4,21]. The relation-
ship between possible tissue tropism and clinical disease is not well
characterised: viral DNA may persist indefinitely, but this archived
virus does not necessarily reflect local disease. Conversely, specific
pathology does not clearly relate to viral replication in local tissues;
for example, anaemia in acute infection was not associated with
high viral titres in bone marrow [22].
Should We Worry about PARV4 in the Long Term?
Despite the lack of consistent evidence for PARV4-mediated
disease, there are several concerns about the implications of this
virus.
Other viruses that make an interspecies jump from animals to
humans have demonstrated the potential to cause severe human
disease, the most notable recent examples being the SARS
coronavirus and highly pathogenic species of influenza. Related
animal parvoviruses have the potential to cause significant host-
specific pathology (e.g., fever, foetal loss, and chronic immuno-
suppression in pigs [17]). It is therefore possible that parvoviruses
that make their way into the human host will ultimately be
responsible for a greater range of significant pathology. Further-
more, the parenteral route of PARV4 transmission and its high
prevalence in subjects coinfected with other blood-borne viruses
puts immunocompromised patients at particular risk of acquiring
infection; these are also the individuals likely to be most susceptible
to clinical manifestations.
Parvoviruses are potentially resistant to traditional viral
inactivation methods employed for plasma-derived products
[1,11,14]. In the Western world, these risks are mitigated by
modern virus inactivation procedures that are likely to be effective
against parvoviruses and by the increasing use of recombinant
clotting factors instead of plasma-derived products. However,
transfusion-mediated transmission remains a potential issue in
developing countries. The extent of this concern is uncertain given
the doubts over the clinical significance of PARV4 infection.
We are left with important unanswered questions. What are the
potential outcomes of infection with PARV4? Are there really
multiple different modes of transmission? How frequently does
viral persistence occur, and does this matter to the host? Further
work is urgently needed to improve our understanding of this
emerging infection.
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